Corporate Overview

Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ management team has a proven track record of managing clinical development, regulatory approval, product launches, and marketing products either directly or through partnerships. Aequus' commercial pipeline is focused on highly specialized therapeutic areas, including neurology, ophthalmology and transplant. The development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide. Through the recent acquisition of TeOra Health, we have a commercial platform to build on for the launch of additional products that are either created internally or brought in through an acquisition or license. 

Aequus is developing a pipeline of prescription medications that address current delivery and compliance challenges....


Aequus’ management team is comprised of highly experienced executives in pharmaceutical and transdermal drug development....


Stock Info

Change (%)
+0.02 (0%)
Data as of
Minimum 20 minute delay

Latest News

Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch

Aequus Closes Financing for Gross Proceeds of C$1,237,500

All News

E-News Subscription